Russian experience of refractory chronic urticaria treatment with omalizumab

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access


Background. To study the efficacy and safety of omalizumab in patients with chronic urticaria, refractory to antihistamines in clinical practice. Methods. In this retrospective clinical analysis, we assessed effectiveness, time to relief of symptoms, dose change after omalizumab administration, and safety in 17 CU patients, 16 with chronic spontaneous urticaria (CSU), 1 with different forms of chronic inducible urticaria (CindU) and 4 with both. Results. Treatment with omalizumab showed excellent effect in 70,6%, significant - in 17,7%, no effect - in 11,7% of CU patients. Eight patients marked effect for 24 hours, 2 - within 2-3 days, 2 - during 2 weeks, 1 - 4 weeks, and 2 patients - for 8 weeks. Eleven patients were receiving omalizumab 300 mg once per 4 weeks, one patient - 150 mg, 4 patients 2 injections of 300 mg, followed by 150 mg of 2, one patient had started treatment with a dose of 150 mg, continued treatment with omalizumab 300 mg. Omalizumab was safe. There was no influence of baseline total IgE levels and the results of test with autosera on the efficacy of omalizumab treatment. Conclusion. Our observation of patients with chronic spontaneous urticaria, with the concomitant or separate physical (induced) hives can resume high efficacy and safety of omalizumab treatment which can be recommended for CU patients, torpid to the first and secondline therapy.

Full Text

Restricted Access

About the authors

I V Danilycheva

Institute of Immunology


O G Elisyutina

Institute of Immunology

N I Ilina

Institute of Immunology

E A Latysheva

Institute of Immunology

T V Latysheva

Institute of Immunology

E S Fedenko

Institute of Immunology

A E Shulzhenko

Institute of Immunology


  1. Zuberbier T., Asero R., Bindslev-Jensen C. et al. EAACI/ GA2LEN/EDF/WAO guideline: management of urticaria. Allergy. 2009, v. 64, p. 1427-1443.
  2. Shankar T., Petrov A. Omalizumab and hypersensitivity reactions. Current Opinion in Allergy and Clinical Immunology. 2013, v. 13, p. 19-24.
  3. Holgate S., Casale T, Wenzel S. et al. The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation. J. Allergy Clin. Immunol. 2005, v. 115, p. 459-465.
  4. Prussin C., Griffith D.T., Boesel K.M. et al. Omalizumab treatment downregulates dendritic cell Fcepsilon RIexpression. J. Allergy Clin. Immunol. 2003, v. 112, p. 1147-1154.
  5. Holgate S., Smith N., Massanari M. et al. Effects of omalizumab on markers of inflammation in patients with allergic asthma. Allergy. 2009, v. 64, p. 1728-1736.
  6. Djukanovic' R., Wilson S.J., Kraft M. et al. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am. J. Respir. Crit Care Med. 2004, v. 170, p. 583-593.
  7. Spector S.L., Tan R.A. Effect of omalizumabon patients with chronic urticaria. Ann. Allergy Asthma Immunol. 2007, v. 99, p. 190-340.
  8. Kaplan A.P., Joseph K., Maykut R.J. et al. Treatment of chronic autoimmune urticaria with omalizumab. J. Allergy Clin. Immunol. 2008, v. 122, p. 569-573.
  9. Gober L.M., Sterba P.M., Eckman J.A., Saini S.S. Effect of anti-IgE (omalizumab) in chronic idiopathic urticaria (CIU) patients. J. Allergy Clin. Immunol. 2008, v. 121, p. 147.
  10. Magerl M., Staubach P., Altrichter S. et al. Effective treatment of therapy resistant chronic spontaneous urticaria with omalizumab. J. Allergy Clin. Immunol. 2010, v. 126, p. 665-666.
  11. Groffik A., Mitzel-Kaoukhov H., Magerl M. et al. Omalizumab: an effective and safe treatment of therapy-resistant chronic spontaneous urticaria. Allergy. 2011, v. 66, p. 303-305.
  12. Maurer M., Rosen K.E., Hsieh H.J. et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N. Engl. J. Med. 2013, v. 368, p. 924-935.
  13. Kaplan A., Ledford D., Ashby M. et al. Omalizumab in patients with symptomatic chronic idiopathic/spontaenous urticaria despite standard combination therapy. J. Allergy Clin. Immunol. 2013, v. 132, p. 101-109.
  14. Fiorino I., Loconte F., Simona Rucco A. et al. Long-term treatment of refractory severe chronic urticaria by omalizumab: analysis oftwo cases. Postep Derm. Alergol. 2014, v. 5, p. 332-334.
  15. Metz M., Ohanyan T., Church M.K. et al. Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: A retrospective clinical analysis. Journal of Dermatological Science. 2014, v. 73, p. 57-62.
  16. Maurer M., Altrichter S., Bieber T. et al. Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase. J. Allergy Clin. Immunol. 2011, v. 128, p. 202-209.
  17. Saini S., Rosen K.E., Hsieh H.J. et al. A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria. J. Allergy Clin. Immunol. 2011, v. 128, p. 567-573.
  18. Goldenberg M. Pharmaceutical Approval Update. P&T®. 2014, v. 39, p. 415-416.

Copyright © Pharmarus Print Media, 2015

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies